<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577589</url>
  </required_header>
  <id_info>
    <org_study_id>D3720C00015</org_study_id>
    <nct_id>NCT01577589</nct_id>
  </id_info>
  <brief_title>A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects</brief_title>
  <official_title>A Phase I, Single-center, 2-part, Randomized, 2-way Crossover Study to Assess the Local Tolerability and Safety (Multiple-dose) and to Assess the Pharmacokinetics, Safety, and Tolerability (Single-dose) of Ceftaroline in Healthy Subjects When Ceftaroline Fosamil is Diluted in Various Infusion Volume</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of
      Ceftaroline 600 mg when administered by varying infusion volumes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single-center, 2-part, Randomized, 2-way Crossover Study to Assess the Local
      Tolerability and Safety (Multiple-dose) and to Assess the Pharmacokinetics, Safety, and
      Tolerability (Single-dose) of Ceftaroline in Healthy Subjects when Ceftaroline Fosamil is
      Diluted in Various Infusion Volume
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour pharmacokinetic profile in terms of (see description) for ceftaroline following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes</measure>
    <time_frame>Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) Time to maximum concentration (tmax) Area under the concentration-time curve from zero to infinity (AUC) Area under the plasma concentration-time curve from zero to time of the last quantifiable concentrations [AUC(0-t)] Area under the plasma concentration-time curve from zero to 12 hours after the start of the infusion [AUC(0-12)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour pharmacokinetic profile in terms of (see description)for ceftaroline following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes</measure>
    <time_frame>Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose</time_frame>
    <description>Apparent terminal elimination rate constant (Lz) Half-life associated with the terminal slope (t½Lz),mean residence time (MRT) Total body clearance of drug from plasma (CL) Volume of distribution based on the terminal phase(Vz) Volume of distribution at steady state (Vss) Cmax ratios of ceftaroline/ceftaroline fosamil and ceftaroline M-1/ceftaroline (RM/D,Cmax) AUC ratios of ceftaroline/ceftaroline fosamil and ceftaroline M-1/ceftaroline (RM/D,AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerability in terms of adverse events including local infusion site tolerability for ceftaroline following ceftaroline 600 mg diluted in various infusion volumes every 12 hours for 72 hours</measure>
    <time_frame>From baseline to 14 days after first dose</time_frame>
    <description>Baseline is defined as - Screening up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile in terms of vital signs, ECG, laboratory variables, physical examination for ceftaroline following ceftaroline 600 mg diluted in various infusion volumes every 12 hours for 72 hours</measure>
    <time_frame>From baseline to 14 days after first dose</time_frame>
    <description>Baseline is defnied as - Screening up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour pharmacokinetic profile in terms of ( see description) for ceftaroline fosamil and ceftaroline M-1following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes</measure>
    <time_frame>Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) Time to maximum concentration (tmax) Area under the concentration-time curve from zero to infinity (AUC) Area under the plasma concentration-time curve from zero to time of the last quantifiable concentrations [AUC(0-t)] Area under the plasma concentration-time curve from zero to 12 hours after the start of the infusion [AUC(0-12)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour pharmacokinetic profile in terms of ( see description) for ceftaroline fosamil and ceftaroline M-1following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes</measure>
    <time_frame>Pre-dose, 20 min, 40 min, 60 min, 65 min, 75 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 18 h, 24 h post-dose</time_frame>
    <description>Apparent terminal elimination rate constant (Lz) Half-life associated with the terminal slope (t½Lz),mean residence time (MRT) Total body clearance of drug from plasma (CL) Volume of distribution based on the terminal phase(Vz) Volume of distribution at steady state (Vss) Cmax ratios of ceftaroline/ceftaroline fosamil and ceftaroline M-1/ceftaroline (RM/D,Cmax) AUC ratios of ceftaroline/ceftaroline fosamil and ceftaroline M-1/ceftaroline (RM/D,AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile in terms of adverse events, vital signs, ECG, laboratory variables, physical exam of ceftaroline following single-dose administration of ceftaroline fosamil 600 mg diluted in various infusion volumes</measure>
    <time_frame>From baseline to 14 days after first dose)</time_frame>
    <description>Baseline is defined as- Screening up.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg ceftaroline fosamil in 50 ml infusion volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in 50 ml infusion volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 ceftaroline fosamil in 250 ml infusion volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in 250 ml infusion volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg ceftaroline in 100 ml infusion volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in 100 ml infusion volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600 mg ceftaroline fosamil in 50 ml infusion volume</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo in 50 ml infusion volume</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600 ceftaroline fosamil in 250 ml infusion volume</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo in 250 ml infusion volume</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600 mg ceftaroline in 100 ml infusion volume</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo in 100 ml infusion volume</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific requirements

          -  Women of childbearing potential must have a negative pregnancy test, be non-lactating,
             and be using a highly effective form of birth control for 3 months prior to
             enrollment, during the study, and for 3 months after completion of all study-related
             proceed

          -  Male volunteers must be willing to use barrier contraception from the first day of
             dosing until 3 months after the last dose of IP.

          -  Have a body mass index (BMI) between 18 and 30 kg/m2, and weigh at least 50 kg

          -  Healthy male and/or female volunteers between the ages of 18 to 75 years inclusive,
             with veins on the back of both hands and both forearms suitable for cannulation or
             repeated venipuncture.

        Exclusion Criteria:

          -  Use of any other investigational compound or participation in another clinical trial
             within 1 month prior to first administration of IP in this study

          -  History of any clinically significant disease or disorder (e.g., neurological,
             haematological, psychiatric, gastrointestinal, hepatic, renal disease)

          -  Positive serology result on screening for serum hepatitis B surface antigen, hepatitis
             C antibody (HCV), or human immunodeficiency virus (HIV)

          -  History or presence of gastrointestinal, hepatic, or renal disease or any other
             condition known to interfere with the absorption, distribution, metabolism or
             excretion of drugs

          -  Any clinically significant abnormalities in the physical examination, lab, 12-lead ECG
             or vital signs as judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Melnick, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca PharmaceuticalsC2C-7161800 Concord PikePO. Box 15437Wilmington De 19850-5437</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Tranter, MBCHB MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research Cumberland Avenue London NW10 EW UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mirjana Kujacic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Research and DevelopmentSE-431 83 MölndalSweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1378&amp;filename=CSR-D3720C00015.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1378&amp;filename=CSR-D3720C00015.pdf</url>
    <description>CSR-D3720C00015.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1378&amp;filename=Combined_D3720C00015_Clinical_Study_Protocol_Redacted_V2.pdf</url>
    <description>Clinical Study Protocol Redacted</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>cross-over study</keyword>
  <keyword>ceftaroline fosamil</keyword>
  <keyword>various infusion volumes</keyword>
  <keyword>local tolerability</keyword>
  <keyword>Cmax</keyword>
  <keyword>tmax</keyword>
  <keyword>AUC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

